ERBB2 and breast carcinoma: In a SOPHIA phase 3 clinical trial, the FcγRIIIa-V/F158 and FcγRIIIa-F/F158 genotype patients showed an improved therapeutic potency of HER-2 positive breast cancer but did not show a significant effect in the v/v genotype patients [147,148].